LINK

Theatro Shines in 2024 RIS Software Leaderboard with 9 Top Rankings

Retrieved on: 
Thursday, December 21, 2023
Leaderboard, Virtual assistant, Research, LINK, RIS, Telephone numbers in Hungary, Customer satisfaction, Safety, Organization, News, ROI, Communication, Retail

RICHARDSON, Texas, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Theatro, a leader in voice-enabled mobile communication solutions, announces its impressive performance in the 2024 RIS Software Leaderboard. This prestigious annual retail customer satisfaction survey of the industry's top software vendors, conducted by RIS, highlights Theatro's formidable presence in retail technology. Demonstrating its ongoing commitment to innovation and customer satisfaction, Theatro has been acknowledged as the #1 Leader in Technology Innovation by Tier 1 retailers, with a perfect 5.0 score, a testament to its consistent leadership and excellence in delivering software solutions for retailers.

Key Points: 
  • Excelling Again in Technology Innovation, ROI, and Customer Satisfaction
    RICHARDSON, Texas, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Theatro, a leader in voice-enabled mobile communication solutions, announces its impressive performance in the 2024 RIS Software Leaderboard.
  • This prestigious annual retail customer satisfaction survey of the industry's top software vendors, conducted by RIS, highlights Theatro's formidable presence in retail technology.
  • Leadership in six categories with #1 rankings and perfect scores of 5.0:
    The RIS News Software Leaderboard is an esteemed annual evaluation compiled by an independent research firm.
  • To view the full 2024 RIS Software Leaderboard and each of Theatro's rankings, visit LINK.

A World’s First: Murata Enables Better Wi-Fi 6E and Wi-Fi 7 Antenna Design with Cutting-Edge Parasitic Element Coupling Device

Retrieved on: 
Thursday, December 7, 2023
Other Manufacturing, Technology, Mobile, Wireless, Other Technology, Telecommunications, Manufacturing, Internet, Hardware, Consumer Electronics, Communication, Wi-Fi 6, ISIN, Tablet, Miniaturization, Parasitism, LINK, Multimedia, IEEE 802.11be, Mobile phone, Transformer, Surveying, Cable television

This state-of-the-art solution improves antenna efficiency by magnetically coupling the parasitic element with the antenna and is the world's first solution designed for Wi-Fi 6E and Wi-Fi 7 products.

Key Points: 
  • This state-of-the-art solution improves antenna efficiency by magnetically coupling the parasitic element with the antenna and is the world's first solution designed for Wi-Fi 6E and Wi-Fi 7 products.
  • Murata’s parasitic element coupling device connects the feeding antenna* to its parasitic elements more effectively than is possible through free space.
  • The resultant, more direct coupling enables the resonance characteristics of the parasitic element to be added to those of the feeding antenna.
  • By sustaining the coupling between the feeding antenna and parasitic element, parasitic element coupling device enables designers to use miniaturized antenna design methods without impacting the communication band of efficiency.

Chainlink Staking v0.2 Is Now Live

Retrieved on: 
Tuesday, November 28, 2023
Stakers, SAN, Oracle Service Bus, LINK, CCIP, Ecosystem, Early access, Generic Access Network, Community, Growth, Chain-link fencing, Modularity, Cryptocurrency

SAN FRANCISCO, Nov. 28, 2023 /PRNewswire/ -- Chainlink, the industry-standard decentralized computing platform, announced today that Chainlink Staking v0.2, the latest upgrade to the protocol's native staking mechanism, is now live. The launch of the v0.2 upgrade begins with a nine-day Priority Migration period for existing v0.1 stakers during which they can migrate their staked LINK and rewards to v0.2, and will progressively expand access to a broader scope of participants, with Early Access and General Access starting on December 7 and December 11 respectively. Chainlink Staking takes place at https://staking.chain.link.

Key Points: 
  • SAN FRANCISCO, Nov. 28, 2023 /PRNewswire/ -- Chainlink , the industry-standard decentralized computing platform, announced today that Chainlink Staking v0.2 , the latest upgrade to the protocol's native staking mechanism, is now live.
  • Staking is a core initiative of Chainlink Economics 2.0 , which is bringing a new layer of cryptoeconomic security to the Chainlink Network.
  • While v0.1 served as the initial Staking program, v0.2 has been rearchitected into a fully modular, extensible, and upgradable Staking platform.
  • Modular architecture to iteratively support future improvements and additions to Chainlink Staking, such as expansion to more services.

Exro Technologies Announces Third Quarter 2023 Financial Results

Retrieved on: 
Friday, November 10, 2023
Research, Safety, Engineering, VEV, ESS, VMC, Electronics, Shewhart individuals control chart, AB, Depreciation, Cell, LINK, Letter, Party, Patent, OEM, UL, MD, Torque, Vicinity Motor Corp., TSX, Certification, Coil, Clothing, Rare-earth element, Electric motor

Exro generated revenue of $2,032,669 for the three months ended September 30, 2023, and $4,800,730 for the nine months ended September 30, 2023.

Key Points: 
  • Exro generated revenue of $2,032,669 for the three months ended September 30, 2023, and $4,800,730 for the nine months ended September 30, 2023.
  • Exro announced the official start of production of the Company's Coil Driver™ technology on September 6, 2023.
  • CALGARY, AB, Nov. 9, 2023 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro"), a leading clean technology company which has developed new generation power control electronics that expand the capabilities of electric motors and batteries, announced today its financial results for the quarter ended September 30, 2023.
  • In January, Exro kicked-off its launch year with a Q1 Letter to Shareholders which outlined 10 strategic objectives for 2023 ( LINK ).

Corsair Gaming Reports Third Quarter 2023 Financial Results; 16.5% Revenue Growth Over Prior Year; Updates Full Year Financial Outlook

Retrieved on: 
Tuesday, November 7, 2023
Technology, Mobile, Wireless, Electronic Games, Audio, Video, Entertainment, Online, Blogging, Apps, Applications, Podcast, Other Technology, Communications, Internet, Hardware, Consumer Electronics, Elgato, Virtuoso, Ecosystem, International, EBITDA, GAAP, Acquisition, FPS, Mouse, Risk, Prompter, ICU Medical, CPU, GPU, K70, LINK, Traction, CRSR, Marketplace, DIY, Corsair Gaming, Bluetooth, Video game, Reinsurance, Corsair, Q3

Net revenue was $363.2 million compared to $311.8 million in the third quarter of 2022, an increase of 16.5%.

Key Points: 
  • Net revenue was $363.2 million compared to $311.8 million in the third quarter of 2022, an increase of 16.5%.
  • Net revenue was $1,042.6 million compared to $976.4 million in the first nine months of 2022, an increase of 6.8%.
  • The robust and successful release of a steady stream of popular new game titles in 2023 is further spurring demand.
  • Corsair will host a conference call to discuss the third quarter 2023 financial results today at 2:00 p.m. Pacific Time.

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

Retrieved on: 
Friday, November 3, 2023
FDA, Society for Immunotherapy of Cancer, Trial of the century, IND, Rapids, Prostate cancer, Antigen, News, Cytokine, HAL, RMIT Platform Technologies Research Institute, Immune system, Nature, Cell, HIV disease progression rates, Poster, SITC, Immunotherapy, B cell, NK, Cancer, Breast cancer, LINK, GM-CSF, Therapy, BCT, Patient, Breast, TSX, HLA, CD86, Vaccine, Medical imaging, Pharmaceutical industry

“We expect our novel immunotherapies to boost the immune system in cancer patients leading to tumor destruction.

Key Points: 
  • “We expect our novel immunotherapies to boost the immune system in cancer patients leading to tumor destruction.
  • Platform Technology: These findings support further development of BriaCell’s platform of next-generation cancer immunotherapies for multiple cancer types, focusing initially on breast, and prostate cancers.
  • In summary, BriaCell’s novel next generation personalized immunotherapy delivers broad immune responses against various solid tumor models via multiple immune activating mechanisms.
  • This opens the path to the clinic for Bria-OTS™, the first generation of BriaCell’s personalized off-the-shelf cellular immunotherapy for breast cancer.

Mercedes-Benz Direct Chat: an internal ChatGPT application for employees

Retrieved on: 
Monday, October 30, 2023
Automotive, General Automotive, Technology, Other Automotive, Software, Artificial Intelligence, Intelligence, Explainable artificial intelligence, Integrity, ChatGPT, Microsoft, Workforce, Artificial intelligence, Environment, Mercedes-Benz, Machine learning, Microsoft Azure, LINK, Privacy, Eye, Mercedes, AI, AG, Online shopping, Sales, Automotive industry

Mercedes-Benz is rolling out an internal web application for its employees – the Mercedes‑Benz Direct Chat.

Key Points: 
  • Mercedes-Benz is rolling out an internal web application for its employees – the Mercedes‑Benz Direct Chat.
  • That's why our employees should be given the opportunity to work with this groundbreaking technology and gain their own experience in a protected environment.
  • To get employees started with this topic and the tool, Mercedes‑Benz is providing them with a variety of training courses.
  • With Turn2Learn, our company is providing employees with appropriate qualifications – including for Mercedes‑Benz Direct Chat."

NATIONAL CHERRY BLOSSOM FESTIVAL HIRES LINK STRATEGIC PARTNERS TO MANAGE 2024 MEDIA AND PUBLIC RELATIONS

Retrieved on: 
Friday, November 3, 2023
LINK, National Cherry Blossom Festival, Festival, DC, Partnership, Tourism

WASHINGTON, Nov. 3, 2023 /PRNewswire/ -- The National Cherry Blossom Festival has chosen LINK Strategic Partners , a DC-based social impact firm to lead public and media relations for the organization.

Key Points: 
  • WASHINGTON, Nov. 3, 2023 /PRNewswire/ -- The National Cherry Blossom Festival has chosen LINK Strategic Partners , a DC-based social impact firm to lead public and media relations for the organization.
  • LINK Strategic Partners, a leading strategic communications and community engagement agency with a strong track record of success in the tourism, cultural and nonprofit sectors, will provide comprehensive PR services to support the Festival's mission of celebrating the arrival of spring.
  • "With LINK as our partner, the National Cherry Blossom Festival aims to strengthen its communications strategies and promote the Festival's cultural and historical significance," said Diana Mayhew, president and CEO of National Cherry Blossom Festival.
  • "Washington, DC, is our hometown, so we couldn't be prouder to support this incredible springtime tradition," said Michael Akin, LINK president.

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, November 3, 2023
Therapy, Survival, Research, Gemcitabine, Oncolytics Biotech, ESMO, Progression-free survival, International, Society for Immunotherapy of Cancer, Congress, European Society for Medical Oncology, FOLFIRINOX, Conference, AB, Engineering, Poster, SITC, Immunotherapy, Clinical trial, Neoplasm, Interim, Annual general meeting, Pancreatic cancer, EMSO, Oncology, Letrozole, Anal cancer, LINK, Tumor microenvironment, Safety, Society, PDAC, ONC, Patient, TSX, IMC, PR, Pharmaceutical industry, Cryptocurrency, Pelareorep

SAN DIEGO and CALGARY, AB, Nov. 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, Nov. 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the third quarter ended September 30, 2023.
  • General and administrative expenses for the third quarter of 2023 were $5.2 million, compared to $2.4 million for the third quarter of 2022.
  • Research and development expenses for the third quarter of 2023 were $5.8 million, compared to $3.7 million for the third quarter of 2022.
  • The net loss for the third quarter of 2023 was $9.9 million, compared to a net loss of $4.4 million for the third quarter of 2022.

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, November 3, 2023
Therapy, Survival, Research, Gemcitabine, Oncolytics Biotech, ESMO, Progression-free survival, International, Society for Immunotherapy of Cancer, Congress, European Society for Medical Oncology, FOLFIRINOX, Conference, AB, Engineering, Poster, SITC, Immunotherapy, Clinical trial, Neoplasm, Interim, Annual general meeting, Pancreatic cancer, EMSO, Oncology, Letrozole, Anal cancer, LINK, Tumor microenvironment, Safety, Society, PDAC, ONC, Patient, TSX, IMC, PR, Pharmaceutical industry, Cryptocurrency, Pelareorep

SAN DIEGO and CALGARY, AB, Nov. 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, Nov. 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the third quarter ended September 30, 2023.
  • General and administrative expenses for the third quarter of 2023 were $5.2 million, compared to $2.4 million for the third quarter of 2022.
  • Research and development expenses for the third quarter of 2023 were $5.8 million, compared to $3.7 million for the third quarter of 2022.
  • The net loss for the third quarter of 2023 was $9.9 million, compared to a net loss of $4.4 million for the third quarter of 2022.